Factors Influencing Adalimumab Treatment Response in Patients with Rheumatoid Arthritis: The Future of Clinical Expertise:

Samer Imad Mohammed; Ali Lateef  Jasim; Mohammad Yawuz Jamal; Saad Abdulrahman Hussain

doi:10.54133/ajms.v5i.232

Authors

Samer Imad Mohammed Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0001-7073-9976
Ali Lateef Jasim Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0003-2473-0799
Mohammad Yawuz Jamal Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq https://orcid.org/0000-0003-0878-8384
Saad Abdulrahman Hussain Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Rafidain University College, Baghdad 10052, Iraq https://orcid.org/0000-0002-1909-417X

DOI:

https://doi.org/10.54133/ajms.v5i.232

Keywords:

Adalimumab, Rheumatoid arthritis, Effectiveness and safety, TNF-α receptors

Abstract

Rheumatoid arthritis (RA) is characterized by persistent joint inflammation, which is a defining feature of this chronic inflammatory condition. Considerable advancements have been made in the field of disease-modifying anti-rheumatic medicines (DMARDs), which effectively mitigate inflammation and forestall further joint deterioration. Anti-tumor necrosis factor-alpha (TNF-α) drugs, which are a class of biological DMARDs (bDMARDs), have been efficaciously employed in the treatment of RA in recent times Adalimumab, a TNF inhibitor, has demonstrated significant efficacy in reducing disease symptoms and halting disease progression in patients with RA. However, its use is associated with major side effects and high costs. In addition, ongoing advancements in therapeutic development have resulted in the production of medications that exhibit enhanced efficacy and safety characteristics. However, further investigation is required before RA can be deemed a manageable pathology. This review presents an analysis of the utilization of adalimumab for the treatment of RA by synthesizing information from relevant literature and emphasizing its effectiveness and safety to improve overall outcomes along with potential cost reductions for patients with RA.

Downloads

Download data is not yet available.

References

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-2038. doi: 10.1016/S0140-6736(16)30173-8. DOI: https://doi.org/10.1016/S0140-6736(16)30173-8

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960-977. doi: 10.1136/annrheumdis-2016-210715. DOI: https://doi.org/10.1136/annrheumdis-2016-210715

Koga T, Kawakami A, Tsokos GC. Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis. Clin Immunol. 2021;225:108680. doi: 10.1016/j.clim.2021.108680. DOI: https://doi.org/10.1016/j.clim.2021.108680

Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149-160. doi: 10.1002/path.2287. DOI: https://doi.org/10.1002/path.2287

Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, et al. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: Prospective cohort study. BMJ. 2019;364:l7. doi: 10.1136/bmj.l67. DOI: https://doi.org/10.1136/bmj.l67

Genovese MC, Fleischmann R, Kivitz A, Lee EB, Hoogstraten HV, Kimura T, et al. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Res Ther. 2020;22:139. doi: 10.1186/s13075-020-02194-z. DOI: https://doi.org/10.1186/s13075-020-02194-z

Dantes E, Tofolean DE, Fildan AP, Craciun L, Dumea E, Tofolean I, et al. Lethal disseminated tuberculosis in patients under biological treatment - Two clinical cases and a short review. J Int Med Res. 2018;46:2961-2969. doi: 10.1177/0300060518771273. DOI: https://doi.org/10.1177/0300060518771273

Papadopoulos CG, Gartzonikas IK, Pappa TK, Markatseli TE, Migkos MP, Voulgari PV, et al. Eight-year survival study of first-line tumour necrosis factor alpha inhibitors in rheumatoid arthritis: Real-world data from a university centre registry. Rheumatol Adv Pract. 2019;3:rkz007. doi: 10.1093/rap/rkz007. DOI: https://doi.org/10.1093/rap/rkz007

Bongartz T, Sutton AJ, Sweeting MJ. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285. doi: 10.1001/jama.295.19.2275. DOI: https://doi.org/10.1001/jama.295.19.2275

Maneiro JR, Souto A, Gomez-Reino JJ. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum. 2017;47:149-156. doi: 10.1016/j.semarthrit.2017.02.007. DOI: https://doi.org/10.1016/j.semarthrit.2017.02.007

Machado MA, Moura CS, Ferré F, Bernatsky S, Rahme E, Acurcio Fde A. Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. Rev Saude Publica. 2016;50:50. doi: 10.1590/S1518-8787.2016050006265. DOI: https://doi.org/10.1590/S1518-8787.2016050006265

Yokoyama S, Ishii Y, Masuda J. Persistence and safety of golimumab in elderly patients with rheumatoid arthritis and renal dysfunction in a real-world setting. Drugs Real World Outcomes. 2023;10(1):51-60. doi: 10.1007/s40801-022-00338-y. DOI: https://doi.org/10.1007/s40801-022-00338-y

Atreya R, Neurath MF. IL-23 blockade in anti-TNF refractory IBD: From mechanisms to clinical reality. J Crohns Colitis. 2022;16(Suppl. 2):ii54-ii63. doi: 10.1093/ecco-jcc/jjac007. DOI: https://doi.org/10.1093/ecco-jcc/jjac007

Michielsens CAJ, Boers N, den Broeder N, Wenink MH, van der Maas A, Mahler EAM, et al. Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomized, non-inferiority trial. Trials. 2020;21(1):90. doi: 10.1186/s13063-019-4000-5. DOI: https://doi.org/10.1186/s13063-019-4000-5

Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-alpha therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int. 2022;42(9):1493-1511. doi: 10.1007/s00296-022-05136-x. DOI: https://doi.org/10.1007/s00296-022-05136-x

Brankov N, Jacob SE. Adalimumab. J Dermatol Nurses Assoc. 2016;8(3):216-220. doi: 10.1097/JDN.0000000000000229. DOI: https://doi.org/10.1097/JDN.0000000000000229

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45. doi.: 10.1002/art.10697. DOI: https://doi.org/10.1002/art.10697

Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74(3):513-518. doi: 10.1136/annrheumdis-2013-204172. DOI: https://doi.org/10.1136/annrheumdis-2013-204172

Cacciapaglia F, Venerito V, Stano S, Fornaro M, Lopalco G, Iannone F. Comparison of adalimumab to other targeted therapies in rheumatoid arthritis: Results from systematic literature review and meta-analysis. J Pers Med. 2022;12(3):353. doi: 10.3390/jpm12030353. DOI: https://doi.org/10.3390/jpm12030353

Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open. 2022;8(1):e002012. doi: 10.1136/rmdopen-2021-002012. DOI: https://doi.org/10.1136/rmdopen-2021-002012

Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford). 2011;50(1):196-203. doi: 10.1093/rheumatology/keq325. DOI: https://doi.org/10.1093/rheumatology/keq325

Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11(Suppl 1):S1. doi: 10.1186/ar2666. DOI: https://doi.org/10.1186/ar2666

van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72(1):104-109. doi: 10.1136/annrheumdis-2012-201445. DOI: https://doi.org/10.1136/annrheumdis-2012-201445

Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum. 2006;54(1):76-81. doi: 10.1002/art.21528. DOI: https://doi.org/10.1002/art.21528

Fletcher A, Lassere M, March L, Hill C, Barrett C, Carroll G, et al. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. Rheumatology (Oxford). 2022;61(10):3939-3951. doi: 10.1093/rheumatology/keac048. DOI: https://doi.org/10.1093/rheumatology/keac048

Blüml S, Scheinecker C, Smolen JS, Redlich K. Targeting TNF receptors in rheumatoid arthritis. Int. Immunol. 2012;24:275-281. doi: 10.1093/intimm/dxs047. DOI: https://doi.org/10.1093/intimm/dxs047

Chen Y, Yuan J, Cai Z, Ma Y. Efficacy of tumor necrosis factor inhibitor combined with intra-articular injection of triamcinolone acetonide in the treatment of refractory rheumatoid arthritis synovitis: a retrospective study. Clin Rheumatol. 2023. doi: 10.1007/s10067-023-06530-x. DOI: https://doi.org/10.1007/s10067-023-06530-x

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639. doi: 10.1002/acr.21641. DOI: https://doi.org/10.1002/acr.21641

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. DOI: https://doi.org/10.1136/annrheumdis-2013-204573

Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, et al. Long-term effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014;41(1):5-14. doi: 10.3899/jrheum.130543. DOI: https://doi.org/10.3899/jrheum.130543

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700-1721. doi: 10.1016/s0149-2918(03)80164-9. DOI: https://doi.org/10.1016/S0149-2918(03)80164-9

Navarro-Millán I, Herrinton LJ, Chen L, Harrold L, Liu L, Curtis JR. Comparative effectiveness of etanercept and adalimumab in patient reported outcomes and injection-related tolerability. PLoS One. 2016;11(3):e0149781. doi: 10.1371/journal.pone.0149781. DOI: https://doi.org/10.1371/journal.pone.0149781

Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Annals of the rheumatic diseases. 2006;65(6):753-759. doi: 10.1136/ard.2005.044404. DOI: https://doi.org/10.1136/ard.2005.044404

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921-926. doi: 10.1136/ard.2006.065615. DOI: https://doi.org/10.1136/ard.2006.065615

Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford). 2012;51(Suppl 5):v22-30. doi: 10.1093/rheumatology/kes115. DOI: https://doi.org/10.1093/rheumatology/kes115

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24(3):390-398. doi: 10.3109/14397595.2013.843760. DOI: https://doi.org/10.3109/14397595.2013.843760

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2012;22(4):498-508. doi: 10.1007/s10165-011-0541-5. DOI: https://doi.org/10.3109/s10165-011-0541-5

Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):e16. doi: 10.1136/annrheumdis-2013-203893. DOI: https://doi.org/10.1136/annrheumdis-2013-203893

Burmester GR, Matucci-Cerinic M, Mariette X, Navarro-Blasco F, Kary S, Unnebrink K, et al. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther. 2014;16(1):R24. doi: 10.1186/ar4452. DOI: https://doi.org/10.1186/ar4452

Haraoui B, Cividino A, Stewart J, Guérette B, Keystone EC. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study. BMC Musculoskelet Disord. 2011;12:261. doi: 10.1186/1471-2474-12-261. DOI: https://doi.org/10.1186/1471-2474-12-261

Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716-3725. doi: 10.1182/blood-2008-09-179754. DOI: https://doi.org/10.1182/blood-2008-09-179754

Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43(4):447-457. doi: 10.1016/j.semarthrit.2013.07.011. DOI: https://doi.org/10.1016/j.semarthrit.2013.07.011

Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844. doi: 10.3389/fimmu.2021.755844. DOI: https://doi.org/10.3389/fimmu.2021.755844

Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272. doi: 10.1186/s13075-016-1170-3. DOI: https://doi.org/10.1186/s13075-016-1170-3

Huang JY, Leong PY, Ker A, Chen HH, Wei JC. The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: A nation-wide, population-based real-world study. Int J Rheum Dis. 2022;25(11):1295-1305. doi: 10.1111/1756-185X.14423. DOI: https://doi.org/10.1111/1756-185X.14423

Taylor PC, Matucci Cerinic M, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimizing treatment outcomes. Ther Adv Musculoskelet Dis. 2022;14:1759720X221114101. doi: 10.1177/1759720X221114101. DOI: https://doi.org/10.1177/1759720X221114101

Fischer R, Kontermann RE, Pfizenmaier K. Selective targeting of TNF receptors as a novel therapeutic approach. Front Cell Dev Biol. 2020;8:401. doi: 10.3389/fcell.2020.00401. DOI: https://doi.org/10.3389/fcell.2020.00401

Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-inhibitors. Front Immunol. 2020;11:312. doi: 10.3389/fimmu.2020.00312. DOI: https://doi.org/10.3389/fimmu.2020.00312

Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213-222. doi: 10.1093/rheumatology/ket260. DOI: https://doi.org/10.1093/rheumatology/ket260

Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460-1468. doi: 10.1001/jama.2011.406. DOI: https://doi.org/10.1001/jama.2011.406

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69(5):817-821. doi: 10.1136/ard.2009.112847. DOI: https://doi.org/10.1136/ard.2009.112847

Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914-1915. doi: 10.1136/annrheumdis-2012-201544. DOI: https://doi.org/10.1136/annrheumdis-2012-201544

Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343(22):1594-1602. doi: 10.1056/NEJM200011303432202. DOI: https://doi.org/10.1056/NEJM200011303432202

Ebell M, Kripke C. Adalimumab for rheumatoid arthritis? Am Fam Physician. 2006;73(3):435-436.

Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13(1):45. doi: 10.1186/s13045-020-00876-4. DOI: https://doi.org/10.1186/s13045-020-00876-4

Julià M, Guilabert A, Lozano F, Suarez-Casasús B, Moreno N, Carrascosa JM, et al. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study. JAMA Dermatol. 2013;149(9):1033-1039. doi: 10.1001/jamadermatol.2013.4632. DOI: https://doi.org/10.1001/jamadermatol.2013.4632

Lu J, Spencer M, Zou Z, Traver M, Brzostowski J, Sun PD. FcγRI FG-loop functions as a pH sensitive switch for IgG binding and release. Front Immunol. 2023;14:1100499. doi: 10.3389/fimmu.2023.1100499. DOI: https://doi.org/10.3389/fimmu.2023.1100499

Morales-Lara MJ, Conesa-Zamora P, García-Simón MS, Pedrero F, Santaclara V, Perez-Guillermo M, et al. Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients. Scand J Rheumatol. 2010;39(6):518-520. doi: 10.3109/03009741003781969. DOI: https://doi.org/10.3109/03009741003781969

Jezernik G, Gorenjak M, Potočnik U. Gene ontology analysis highlights biological processes influencing non-response to anti-TNF therapy in rheumatoid arthritis. Biomedicines. 2022;10(8):1808. doi: 10.3390/biomedicines10081808. DOI: https://doi.org/10.3390/biomedicines10081808

Kim J, Lee JY, Kim HG, Kwak MW, Kang TH. Fc receptor variants and disease: A crucial factor to consider in the antibody therapeutics in clinic. Int J Mol Sci. 2021;22(17):9489. doi: 10.3390/ijms22179489. DOI: https://doi.org/10.3390/ijms22179489

Márquez Pete N, Maldonado Montoro MDM, Pérez Ramírez C, Martínez Martínez F, Martínez de la Plata JE, Daddaoua A, et al. Influence of the FCGR2A rs1801274 and FCGR3A rs396991 polymorphisms on response to abatacept in patients with rheumatoid arthritis. J Pers Med. 2021;11(6):573. doi: 10.3390/jpm11060573. DOI: https://doi.org/10.3390/jpm11060573

Li X, Kimberly RP. Targeting the Fc receptor in autoimmune disease. Expert Opin Ther Targets. 2014;18(3):335-350. doi: 10.1517/14728222.2014.877891. DOI: https://doi.org/10.1517/14728222.2014.877891

Ravaei A, Pulsatelli L, Assirelli E, Ciaffi J, Meliconi R, Salvarani C, et al. MTHFR c.665C>T and c.1298A>C polymorphisms in tailoring personalized anti-TNF-α therapy for rheumatoid arthritis. Int J Mol Sci. 2023;24(4):4110. doi: 10.3390/ijms24044110. DOI: https://doi.org/10.3390/ijms24044110

Dávila-Fajardo CL, van der Straaten T, Baak-Pablo R, Medarde Caballero C, Cabeza Barrera J, Huizinga TW, et al. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics. 2015;16(4):373-381. doi: 10.2217/pgs.14.178. DOI: https://doi.org/10.2217/pgs.14.178

Montes A, Perez-Pampin E, Narváez J, Cañete JD, Navarro-Sarabia F, Moreira V, et al. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics. 2014;24(5):238-245. doi: 10.1097/FPC.0000000000000042. DOI: https://doi.org/10.1097/FPC.0000000000000042

Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005;52(9):2693-2696. doi: 10.1002/art.21266. DOI: https://doi.org/10.1002/art.21266

Smiljanovic B, Grün JR, Biesen R, Schulte-Wrede U, Baumgrass R, Stuhlmüller B, et al. The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J Mol Med (Berl). 2012;90(11):1295-1309. doi: 10.1007/s00109-012-0907-y. DOI: https://doi.org/10.1007/s00109-012-0907-y

Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A, Kuban RJ, Tandon N, et al. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2010;87(3):311-321. doi: 10.1038/clpt.2009.244. DOI: https://doi.org/10.1038/clpt.2009.244

Yoon BR, Yoo SJ, Choi Yh, Chung YH, Kim J, Yoo IS, Kang SW, et al. Functional phenotype of synovial monocytes modulating inflammatory T-cell responses in rheumatoid arthritis (RA). PLoS One. 2014;9(10):e109775. doi: 10.1371/journal.pone.0109775. DOI: https://doi.org/10.1371/journal.pone.0109775

Sugimoto C, Hasegawa A, Saito Y, Fukuyo Y, Chiu KB, Cai Y, Breed MW, et al. Differentiation kinetics of blood monocytes and dendritic cells in Macaques: Insights to understanding human myeloid cell development. J Immunol. 2015;195(4):1774-1781. doi: 10.4049/jimmunol.1500522. DOI: https://doi.org/10.4049/jimmunol.1500522

Loke P, Niewold TB. By CyTOF: Heterogeneity of human monocytes. Arterioscler Thromb Vasc Biol. 2017;37(8):1423-1424. doi: 10.1161/ATVBAHA.117.309645. DOI: https://doi.org/10.1161/ATVBAHA.117.309645

Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376-381. doi: 10.1038/nature12873. DOI: https://doi.org/10.1038/nature12873

Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet. 2007;80(5):867-875. doi: 10.1086/516736. DOI: https://doi.org/10.1086/516736

Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004;75(3):504-507. doi: 10.1086/423790. DOI: https://doi.org/10.1086/423790

Abbasifard M, Imani D, Bagheri-Hosseinabadi Z. PTPN22 gene polymorphism and susceptibility to rheumatoid arthritis (RA): Updated systematic review and meta-analysis. J Gene Med. 2020;22(9):e3204. doi: 10.1002/jgm.3204. DOI: https://doi.org/10.1002/jgm.3204

Diaz-Gallo LM, Martin J. PTPN22 splice forms: a new role in rheumatoid arthritis. Genome Med. 2012;4:13. doi: 10.1186/gm312. DOI: https://doi.org/10.1186/gm312

Tizaoui K, Terrazzino S, Cargnin S, Lee KH, Gauckler P, Li H, et al. The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review. Semin Arthritis Rheum. 2021;51(3):513-522. doi: 10.1016/j.semarthrit.2021.03.004. DOI: https://doi.org/10.1016/j.semarthrit.2021.03.004

Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68(1):69-74. doi: 10.1136/ard.2007.084715. DOI: https://doi.org/10.1136/ard.2007.084715

Gao S, Liang W, Xu T, Xun C, Cao R, Deng Q, et al. Associations of tumor necrosis factor alpha gene polymorphisms and ankylosing spondylitis susceptibility: A meta-analysis based on 35 case-control studies. Immunological Invest. 2021;51(4):859-882. doi: 10.1080/08820139.2021.1882485. DOI: https://doi.org/10.1080/08820139.2021.1882485

Bergman MJ, Kivitz AJ, Pappas DA, Kremer JM, Zhang L, Jeter A, et al. Clinical utility and cost savings in predicting inadequate response to anti-TNF therapies in rheumatoid arthritis. Rheumatol Ther. 2020;7(4):775-792. doi: 10.1007/s40744-020-00226-3. DOI: https://doi.org/10.1007/s40744-020-00226-3

Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180-210. doi: 10.1159/000289205. DOI: https://doi.org/10.1159/000289205

Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov. 2007;6(1):75-92. doi: 10.1038/nrd2196. DOI: https://doi.org/10.1038/nrd2196

Lim SH, Kim K, Choi CI. Pharmacogenomics of monoclonal antibodies for the treatment of rheumatoid arthritis. J Pers Med. 2022;12(8):1265. doi: 10.3390/jpm12081265. DOI: https://doi.org/10.3390/jpm12081265

Miler M, Nikolac Gabaj N, Ćelap I, Grazio S, Tomašić V, Bišćanin A, et al. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy. Rheumatol Int. 2021;41(12):2195-2203. doi: 10.1007/s00296-021-05016-w. DOI: https://doi.org/10.1007/s00296-021-05016-w

Hadinedoushan H, Noorbakhsh P, Soleymani-Salehabadi H. Tumor necrosis factor alpha gene polymorphism and association with its serum level in Iranian population with rheumatoid arthritis. Arch Rheumatol. 2016;31(4):306-313. doi: 10.5606/ArchRheumatol.2016.5907. DOI: https://doi.org/10.5606/ArchRheumatol.2016.5907

Membrive Jiménez C, Pérez Ramírez C, Sánchez Martín A, Vieira Maroun S, Arias Santiago S, Ramírez Tortosa MC, et al. Clinical application of pharmacogenetic markers in the treatment of dermatologic pathologies. Pharmaceuticals (Basel). 2021;14(9):905. doi: 10.3390/ph14090905. DOI: https://doi.org/10.3390/ph14090905

Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol. 2006;35(6):435-440. doi: 10.1080/03009740600904284. DOI: https://doi.org/10.1080/03009740600904284

Seitz M, Wirthmüller U, Möller B, Villiger PM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007;46(1):93-96. doi: 10.1093/rheumatology/kel175. DOI: https://doi.org/10.1093/rheumatology/kel175

O'Rielly DD, Roslin NM, Beyene J, Pope A, Rahman P. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J. 2009;9(3):161-167. doi: 10.1038/tpj.2009.7. DOI: https://doi.org/10.1038/tpj.2009.7

Saddala MS, Huang H. Identification of novel inhibitors for TNFα, TNFR1 and TNFα-TNFR1 complex using pharmacophore-based approaches. J Transl Med. 2019;17(1):215. doi: 10.1186/s12967-019-1965-5. DOI: https://doi.org/10.1186/s12967-019-1965-5

Chen W, Xu H, Wang X, Gu J, Xiong H, Shi Y. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis. Int Immunopharmacol. 2015;28(1):146-153. doi: 10.1016/j.intimp.2015.05.049. DOI: https://doi.org/10.1016/j.intimp.2015.05.049

Prieto-Pérez R, Cabaleiro T, Daudén E, Abad-Santos F. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J. 2013;13(4):297-305. doi: 10.1038/tpj.2012.53. DOI: https://doi.org/10.1038/tpj.2012.53

Ruiz A, Palacios Y, Garcia I, Chavez-Galan L. Transmembrane TNF and its receptors TNFR1 and TNFR2 in mycobacterial infections. Int J Mol Sci. 2021;22(11):5461. doi: 10.3390/ijms22115461. DOI: https://doi.org/10.3390/ijms22115461

El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-α gene polymorphisms and expression. Springerplus. 2016;5(1):1508. doi: 10.1186/s40064-016-3197-y. DOI: https://doi.org/10.1186/s40064-016-3197-y

Ongaro A, De Mattei M, Pellati A, Caruso A, Ferretti S, Masieri FF, et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? Rheumatol Int. 2008;28(9):901-908. doi: 10.1007/s00296-008-0552-5. DOI: https://doi.org/10.1007/s00296-008-0552-5

Canault M, Leroyer AS, Peiretti F, Lesèche G, Tedgui A, Bonardo B, et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol. 2007;171(5):1713-1723. doi: 10.2353/ajpath.2007.070021. DOI: https://doi.org/10.2353/ajpath.2007.070021

Sethi JK, Hotamisligil GS. Metabolic messengers: tumour necrosis factor. Nat Metab. 2021;3(10):1302-1312. doi: 10.1038/s42255-021-00470-z. DOI: https://doi.org/10.1038/s42255-021-00470-z

Ben-Baruch A. Tumor necrosis factor α: Taking a personalized road in cancer therapy. Front Immunol. 2022;13:903679. doi: 10.3389/fimmu.2022.903679. DOI: https://doi.org/10.3389/fimmu.2022.903679

Steeland S, Libert C, Vandenbroucke RE. A new venue of TNF targeting. Int J Mol Sci. 2018;19(5):1442. doi: 10.3390/ijms19051442. DOI: https://doi.org/10.3390/ijms19051442

Pojskic L, Gavrankapetanovic I, Lojo-Kadric N, Hadziselimovic R, Bajrovic K. A genotyping assay for missense mutation in WISP3 gene associated with childhood onset pseudorheumatoid arthropathy. J Health Sci. 2015;5(2):59-64. doi: 10.17532/jhsci.2015.241. DOI: https://doi.org/10.17532/jhsci.2015.241

Curtis JR, Hobar C, Hansbrough K. Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics. Curr Med Res Opin. 2011;27(1):71-78. doi: 10.1185/03007995.2010.534959. DOI: https://doi.org/10.1185/03007995.2010.534959

Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2008;67(4):478-484. doi: 10.1136/ard.2007.074104. DOI: https://doi.org/10.1136/ard.2007.074104

Canhão H, Rodrigues AM, Santos MJ, Carmona-Fernandes D, Bettencourt BF, Cui J, et al. TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy. Biomed Res Int. 2015;2015:490295. doi: 10.1155/2015/490295. DOI: https://doi.org/10.1155/2015/490295

Ochi S, Saito K, Mizoguchi F, Kato S, Tanaka Y. Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. Arthritis Res Ther. 2020;22(1):41. doi: 10.1186/s13075-020-2122-5. DOI: https://doi.org/10.1186/s13075-020-2122-5

Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signaling pathways. Ann Rheum Dis. 2010;69(7):1315-1320. doi: 10.1136/ard.2009.117309. DOI: https://doi.org/10.1136/ard.2009.117309

Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human antitumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563-2571.

Popescu CC, Mogoșan CD, Enache L, Codreanu C. Comparison of efficacy and safety of original and biosimilar adalimumab in active rheumatoid arthritis in a real-world national cohort. Medicina (Kaunas). 2022;58(12):1851. doi: 10.3390/medicina58121851. DOI: https://doi.org/10.3390/medicina58121851

Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34(5):1040-1050.